Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15132065 | 0.89 | CA9 (0.51) | HPGDRXRARXRBP2RX7MEN1 | |
| SCHEMBL15373872 | 0.86 | P2RX7 (0.46) | HPGDRXRARXRBP2RX7MEN1 | |
| SCHEMBL10101806 | 0.86 | EGFR (0.51) | HPGDRXRARXRBP2RX7PDE4D | |
| SCHEMBL113440 | 0.85 | P2RX7 (0.45) | HPGDRXRARXRBP2RX7MEN1 | |
| SCHEMBL15065246 | 0.80 | PARP10 (0.51) | RXRAP4HTMAOC3 | |
| SCHEMBL15088138 | 0.77 | NPC1 (0.50) | HPGDRXRARXRBP2RX7NPC1 | |
| SCHEMBL1843931 | 0.77 | MEN1 (0.56) | HPGDRXRARXRBMEN1NPC1 | |
| SCHEMBL6257319 | 0.76 | ITGB1 (0.40) | NPC1NFKB1RAB9ANFKB2KMT2A | |
| SCHEMBL7288458 | 0.76 | CLCN2 (0.60) | HPGDRXRARXRBMEN1NPC1 | |
| SCHEMBL6128444 | 0.75 | PDE4A (0.47) | MEN1TP53KMT2APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2921480-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-10-11 | — | — | EP | disclosed |
| EP-2921480-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-10-11 | — | — | EP | disclosed |
| US-9777005-B2 | Bicyclic heterocyclic compound containing a substituted pyrrole ring | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9777005-B2 | Bicyclic heterocyclic compound containing a substituted pyrrole ring | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9777005-B2 | Bicyclic heterocyclic compound containing a substituted pyrrole ring | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9732086-B2 | — | — | 2017-08-15 | — | — | US | disclosed |
| US-9732086-B2 | — | — | 2017-08-15 | — | — | US | disclosed |
| US-9732086-B2 | — | — | 2017-08-15 | — | — | US | disclosed |
| US-9688644-B2 | Synthesis of Tetracyclines and intermediates thereto | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688644-B2 | Synthesis of Tetracyclines and intermediates thereto | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-27 | — | — | US | disclosed |
| US-9073829-B2 | Synthesis of tetracyclines and intermediates thereto | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-07-07 | — | — | US | disclosed |
| US-8828988-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| WO-2014077401-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2014-05-22 | — | — | WO | disclosed |
| US-20130296279-A1 | SUBSTITUTED TETRACYCLINES | CONCERT PHARMACEUTICALS INC. | 2013-11-07 | — | — | US | disclosed |
| US-8367654-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| WO-2012065028-A2 | SUBSTITUTED TETRACYCLINES | CONCERT PHARMACEUTICALS INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115818-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-03 | — | — | US | disclosed |
| EP-2424834-A2 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | President and Fellows of Harvard College (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126607-A2 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115818-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | TET1, TET3, TYMS | HPGD 1380/4885RXRA 2402/4885RXRB 2934/4885 |
| US-20130296279-A1 | SUBSTITUTED TETRACYCLINES | TET1, TET3, SLC10A2 | HPGD 3051/4885RXRA 3309/4885RXRB 3911/4885 |
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TET1, TET3, HDAC8 | HPGD 2983/4885RXRA 1581/4885RXRB 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.